Paulo Maciag

3.7k total citations · 1 hit paper
69 papers, 2.1k citations indexed

About

Paulo Maciag is a scholar working on Hematology, Molecular Biology and Immunology. According to data from OpenAlex, Paulo Maciag has authored 69 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Hematology, 34 papers in Molecular Biology and 17 papers in Immunology. Recurrent topics in Paulo Maciag's work include Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (26 papers) and Cervical Cancer and HPV Research (11 papers). Paulo Maciag is often cited by papers focused on Multiple Myeloma Research and Treatments (38 papers), Protein Degradation and Inhibitors (26 papers) and Cervical Cancer and HPV Research (11 papers). Paulo Maciag collaborates with scholars based in United States, France and Spain. Paulo Maciag's co-authors include Yvonne Paterson, Siniša Radulović, John Rothman, Anu Wallecha, Vafa Shahabi, Sandra Rivera, Philippe Moreau, Luisa L. Villa, Matthew M. Seavey and Cyrille Touzeau and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Paulo Maciag

67 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial

2020 256 citations Shaji Kumar, Simon J. Harrison et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Paulo Maciag United States	24	907	694	652	585	470	69	2.1k
Reiko Namikawa United States	26	661 0.7×	592 0.9×	1.8k 2.8×	549 0.9×	111 0.2×	51	3.5k
Hyam I. Levitsky United States	18	1.0k 1.1×	360 0.5×	3.1k 4.8×	1.8k 3.0×	323 0.7×	25	4.0k
Patrick Saulnier France	28	1.1k 1.2×	199 0.3×	183 0.3×	480 0.8×	113 0.2×	48	2.5k
Robert W. Tindle Australia	29	738 0.8×	329 0.5×	1.5k 2.3×	494 0.8×	92 0.2×	79	2.8k
Michael Buschle Austria	27	1.3k 1.4×	580 0.8×	1.0k 1.6×	472 0.8×	77 0.2×	50	2.8k
Danuta Kozbor United States	31	778 0.9×	136 0.2×	1.3k 2.0×	608 1.0×	146 0.3×	70	2.5k
B. Kim Lee Sim United States	26	1.3k 1.4×	122 0.2×	1.0k 1.6×	344 0.6×	107 0.2×	36	3.0k
Sergey Gorlatov United States	20	813 0.9×	116 0.2×	752 1.2×	658 1.1×	240 0.5×	30	2.4k
Arjen Q. Bakker Netherlands	25	707 0.8×	211 0.3×	1.3k 2.0×	531 0.9×	49 0.1×	49	2.7k
Richard Rudersdorf United States	25	659 0.7×	617 0.9×	1.4k 2.1×	154 0.3×	39 0.1×	32	2.7k

Countries citing papers authored by Paulo Maciag

Since Specialization

Citations

This map shows the geographic impact of Paulo Maciag's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paulo Maciag with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paulo Maciag more than expected).

Fields of papers citing papers by Paulo Maciag

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paulo Maciag. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paulo Maciag. The network helps show where Paulo Maciag may publish in the future.

Co-authorship network of co-authors of Paulo Maciag

This figure shows the co-authorship network connecting the top 25 collaborators of Paulo Maciag. A scholar is included among the top collaborators of Paulo Maciag based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paulo Maciag. Paulo Maciag is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sureda, Anna, Albert Oriol, Mercedes Gironella, et al.. (2024). OA-55 Iberdomide, Daratumumab, and Dexamethasone (IberDd) in Transplant-Ineligible (TNE) Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial. Clinical Lymphoma Myeloma & Leukemia. 24. S35–S35. 1 indexed citations

Amatangelo, Michael, Nicholas Stong, Paulo Maciag, et al.. (2024). Iberdomide, Daratumumab, and Dexamethasone Shows Deep Antimyeloma Activity across Molecular Patient Subsets with Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the CC-220-MM-001 Trial. Blood. 144(Supplement 1). 1973–1973. 4 indexed citations

Bjorklund, Chad C., Michael Amatangelo, Hsiling Chiu, et al.. (2021). Pre-Clinical and Clinical Immunomodulatory Effects of Pomalidomide or CC-92480 in Combination with Bortezomib in Multiple Myeloma. Blood. 138(Supplement 1). 1613–1613. 6 indexed citations

Moreau, Philippe, Simon J. Harrison, Michèle Cavo, et al.. (2019). Updated Analysis of Bellini, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 1888–1888. 28 indexed citations

Kaufman, Jonathan L., Cristina Gasparetto, Fredrik Schjesvold, et al.. (2019). Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 926–926. 16 indexed citations

Touzeau, Cyrille, Paulo Maciag, Martine Amiot, & Philippe Moreau. (2018). Targeting Bcl-2 for the treatment of multiple myeloma. Leukemia. 32(9). 1899–1907. 91 indexed citations

Kaufman, Jonathan L., Cristina Gasparetto, Joseph Mıkhael, et al.. (2017). Phase 1 Study of Venetoclax in Combination with Dexamethasone As Targeted Therapy for t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 130. 3131–3131. 12 indexed citations

Termini, Lara, Adhemar Longatto‐Filho, Paulo Maciag, et al.. (2011). Deregulated expression of superoxide dismutase-2 correlates with different stages of cervical neoplasia.. SHILAP Revista de lepidopterología. 30(6). 275–81. 16 indexed citations

Shahabi, Vafa, Paulo Maciag, Sandra Rivera, & Anu Wallecha. (2010). Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. PubMed. 1(4). 237–245. 51 indexed citations

10.

Shahabi, Vafa, Matthew M. Seavey, Paulo Maciag, Sandra Rivera, & Anu Wallecha. (2010). Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Therapy. 18(1). 53–62. 63 indexed citations

11.

Seavey, Matthew M., Zhen-Kun Pan, Paulo Maciag, et al.. (2009). A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors. Clinical Cancer Research. 15(3). 924–932. 48 indexed citations

12.

Seavey, Matthew M., et al.. (2009). An Anti-Vascular Endothelial Growth Factor Receptor 2/Fetal Liver Kinase-1 Listeria monocytogenes Anti-Angiogenesis Cancer Vaccine for the Treatment of Primary and Metastatic Her-2/neu+ Breast Tumors in a Mouse Model. The Journal of Immunology. 182(9). 5537–5546. 60 indexed citations

13.

Maciag, Paulo, Zhen-Kun Pan, Jessica R. Weaver, et al.. (2009). Listeria monocytogenes Delivery of HPV-16 Major Capsid Protein L1 Induces Systemic and Mucosal Cell-Mediated CD4 ⁺ and CD8 ⁺ T-Cell Responses After Oral Immunization. Viral Immunology. 22(3). 195–204. 16 indexed citations

14.

Termini, Lara, Paulo Maciag, Fernando Augusto Soares, et al.. (2009). Analysis of human kallikrein 7 expression as a potential biomarker in cervical neoplasia. International Journal of Cancer. 127(2). 485–490. 19 indexed citations

15.

Maciag, Paulo, Siniša Radulović, & John Rothman. (2009). The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine. 27(30). 3975–3983. 259 indexed citations

16.

Maciag, Paulo, Matthew M. Seavey, Zhen-Kun Pan, Soldano Ferrone, & Yvonne Paterson. (2008). Cancer Immunotherapy Targeting the High Molecular Weight Melanoma-Associated Antigen Protein Results in a Broad Antitumor Response and Reduction of Pericytes in the Tumor Vasculature. Cancer Research. 68(19). 8066–8075. 74 indexed citations

17.

Castro, Francisco, et al.. (2008). Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. British Journal of Cancer. 99(5). 741–749. 59 indexed citations

18.

Araujo‐Souza, Patrícia Savio de, Paulo Maciag, Karina Braga Ribeiro, et al.. (2008). Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer. BMC Cancer. 8(1). 246–246. 28 indexed citations

19.

Sichero, Laura, et al.. (2008). Human papillomavirus type 16 variants in cervical cancer from an admixtured population in Brazil. Journal of Medical Virology. 80(9). 1639–1645. 27 indexed citations

20.

Maciag, Paulo, et al.. (2002). Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus Infection. The Journal of Infectious Diseases. 186(2). 164–172. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact